The Lead Episode 39: The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease-The Lead Episode 39 Speaker Information

The Lead Episode 39 Speaker Information

Pdf Summary

The article being discussed is titled "The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease." The authors of the article are Soroosh Kiani, MD, MS, Michael N. Sayegh, MS, PHD, Rand Ibrahim, MD, Neal K. Bhatia, MD, Faisal M. Merchant, MD, Anand D. Shah, MD, Stacy B. Westerman, MD, MPH, David B. De Lurgio, MD, Anshul M. Patel, MD, Christine M. Thompkins, MD, Angel R. Leon, MD, Michael S. Lloyd, MD, and Mikhael F. El-Chami, MD. The article was published in the journal JACC: Clinical Electrophysiology.<br /><br />The discussion is hosted by Jason T. Jacobson, MD, FHRS from the Westchester Medical Center-New York Medical College. The contributors to the discussion are Gerald V Naccarelli, MD, FHRS from Pennsylvania State University Milton S. Hershey Medical Center and David J. Callans, MD, FHRS, CCDS from the Hospital of the University of Pennsylvania.<br /><br />The disclosed financial relationships of the contributors include various honoraria/speaking/consulting engagements and research support from companies such as American College of Cardiology, Zoll Medical Corporation, Abbott, Phillips, Ascesion, Sanofi, GlaxoSmithKline, Milestone, InCarda Therapeutics, Heart Rhythm Society, Thermedical, AtriCure Inc., Wolters Kluver, and others.<br /><br />Overall, this discussion focuses on the feasibility and safety of using the medication Flecainide in patients with varying degrees of coronary disease. The contributors bring their expertise and experiences to the conversation in order to provide insights and recommendations on this topic.

Keywords

Feasibility

Safety

Flecainide

Patients

Coronary Disease

Varying Degrees

Article

JACC: Clinical Electrophysiology

Discussion

Jason T. Jacobson